Skip navigation

BPGbio Announces Commercial Availability of NAi, BPGbio’s Pioneering Interrogative Biology Platform

Biopharma’s only fully-integrated, AI-powered drug and diagnostics discovery engine now fully scaled for industry, government, and academic partners

September 28, 2023 07:00 AM Eastern Daylight Time

BOSTON, Mass.—(BUSINESS WIRE)—BPGbio, Inc., a leading AI-powered biopharma company that focuses on oncology, neurology and rare diseases, today announced the commercial launch of the NAi (pronounced “nye”) Interrogative Biology® Platform, the company’s AI-powered platform technology for broad scale development and repurposing of drugs, identification of diagnostic biomarkers, and health analytics. The platform has already delivered groundbreaking results in early-access customer research collaborations with leading government, industry, and academic partners such as the United States Department of Defense (DoD), Sanofi, and Harvard Medical School.

“The NAi Interrogative Biology Platform was developed to embrace the true story of patient biology by using mathematics and technology to de-risk therapeutics and diagnostics development”
Tweet this

“The NAi Interrogative Biology Platform’s large patient resources and databases, multi-omic platforms, AI methodologies, complementary partnerships, and great leaders and entrepreneurs, are set to transform healthcare for all, irrespective of geography,” said Chas Bountra, Ph.D., Pro-Vice Chancellor for Innovation, Professor of Translational Medicine, and Director of the Centre for Medicines Discovery in the Nuffield Department of Clinical Medicine at the University of Oxford. “We in Oxford are delighted to work with brilliant colleagues at BPGbio and Oak Ridge National Laboratory to make available all our relevant resources and expertise to catalyse this vision.”

The NAi platform consists of an industry leading and clinically annotated proprietary biobank, with purpose-built Bayesian AI and is using the world’s fastest supercomputer, Frontier, at Oak Ridge National Laboratory (ORNL), making it the only fully-integrated high performance computing (HPC) platform in the biopharmaceutical industry for AI-driven target nomination, discovery, and molecule design. Uniting the best-in-class in biology and technology for hypothesis-free discovery, it has delivered more than 100 drug and diagnostics targets/candidates for BPGbio, including its lead franchise drug candidate – BPM31510 IV – currently in Phase 2b and Phase 2a trials for glioblastoma multiforme (GBM) and pancreatic cancer, respectively.

“The NAi Interrogative Biology Platform was developed to embrace the true story of patient biology by using mathematics and technology to de-risk therapeutics and diagnostics development,” said Niven R. Narain, Ph.D., President and CEO of BPGbio. “By broadly offering this platform for industry collaboration, we hope to significantly improve the speed and efficiency of therapeutics and diagnostics development. We seek to minimize the disease burden and psychosocial strain of disease to patients and families, while helping to reduce healthcare costs for patients and healthcare systems around the world.”

BPGbio has successfully collaborated with government, industry and academic partners using the NAi Interrogative Biology® Platform to validate its robustness. These partners included government partners the U.S. Department of Defense, U.S. Department of Veterans Affairs, and Genomics England; industry partners AstraZeneca, Boehringer Ingelheim, Sanofi, and Becton Dickinson; and academic partners Harvard University, Stanford University, and Oxford University.

“The NAi Interrogative Biology Platform promises to combine state-of-the-art causal inference AI with the most powerful computing and robust biological and phenotypic data available to reach unprecedented depth in diagnostic and therapeutic science,” said Jeremy Smith, Ph.D., Governor’s Chair and Director, University of Tennessee/Oak Ridge National Laboratory Center for Molecular Biophysics.

In addition to therapeutic assets, the NAi Interrogative Biology® platform has also delivered many diagnostic biomarkers, including the first to market AI-discovered diagnostic biomarker test – pstateDx, BPGbio’s prostate cancer diagnostic test which is currently being commercially launched in Mexico.

For more information about BPGbio and the NAI Interrogative Biology® Platform, visit www.bpgbio.com.

About BPGbio, Inc.

BPGbio is a leading AI-powered clinical stage biopharma and diagnostics company focused on oncology, neurology, and rare diseases. The company has a deep portfolio of AI-developed pipeline of therapeutics, including several in late-stage development. BPGBio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology® Platform, protected by over 400 US and international patents; the world’s largest clinically annotated non-governmental biobank; and access to the most powerful supercomputing in the world. With these tools, BPGbio is redefining how patient biology can be modeled using unbiased AI. Headquartered in Boston, the company is at the forefront of a new era in medicine, combining biology, data, and AI to transform the way we understand aging, human performance, and diagnose and treat disease. For more information, visit bpgbio.com.

Contact
media@bpgbio.com